The Implications of Recent Datasets for the Current and Future Management of Non-Hodgkin Lymphoma — Webinar Video Proceedings

Faculty

TARGET AUDIENCE
This program is intended for medical oncologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the diagnosis and treatment of lymphoma.

LEARNING OBJECTIVES

• Evaluate published clinical research data with Bruton tyrosine kinase (BTK) inhibitors as a component of first-line therapy for mantle cell lymphoma (MCL), and assess the current and future role of various BTK inhibitor-based strategies for patients with newly diagnosed disease.
• Identify patients with newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) for whom CD79b-targeted therapy would be appropriate.
• Understand published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for follicular lymphoma (FL), and employ this information as part of patient education discussions.
• Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates for patients with R/R DLBCL.
• Evaluate the mechanism of action of and available clinical trial findings with bispecific antibodies targeting CD20 x CD3 for patients with FL, DLBCL and other forms of non-Hodgkin lymphoma (NHL), and determine the role of these agents in disease management.
• Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor T-cell therapy for various NHL subtypes, and counsel appropriately selected patients regarding the potential benefits of this therapeutic strategy.
• Recall new data with agents and strategies currently under investigation for various NHL subtypes, and discuss ongoing trial opportunities with eligible patients.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/PostConfNHL25/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Carla Casulo, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Assistant Director, Cancer Research Training and Education
University of Rochester
Wilmot Cancer Institute
Rochester, New York

Consulting Agreements: AbbVie Inc, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Roche Laboratories Inc; Contracted Research: Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc; Honoraria: AbbVie Inc, Genentech, a member of the Roche Group, Incyte Corporation, Roche Laboratories Inc.

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc; Contracted Research: BeOne, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeOne, Bristol Myers Squibb, Roche Laboratories Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from ADC Therapeutics and AstraZeneca Pharmaceuticals LP.

Release date: October 2025
Expiration date: October 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Casulo

Ahmed S et al. Lisocabtagene maraleucel in R/R FL (TRANSCEND FL): Impact of prior lines of therapy, bendamustine exposure, and disease progression ≤ 24 months of initial systemic therapy. International Conference on Malignant Myeloma (ICML) 2025;Abstract 142.

Burke JM et al. MORNINGSUN: Open-label phase II trial of the efficacy and safety of subcutaneous mosunetuzumab (MOSUN SC) as frontline (1L) treatment in symptomatic patients with marginal zone lymphoma (MZL). EHA 2025;Abstract S232.

Dreyling M et al. Efficacy of rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk mantle cell lymphoma: An analysis of the phase 3 ECHO trial. EHA 2025;Abstract S233.

Flinn IW et al. Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study. ASCO 2025;Abstract 7014.

Heß G et al. Fixed-duration subcutaneous mosunetuzumab demonstrates clinically relevant efficacy in patients with relapsed/refractory follicular lymphoma with high-risk features: Pivotal phase II study update. EHA 2025;Abstract PS1872.

Jain P et al. Acalabrutinib in combination with rituximab is highly effective frontline treatment for older patients with mantle cell lymphoma. ICML 2025;Abstract 272.

Palomba ML et al. Lisocabtagene maraleucel (LISO-CEL) in patients (PTS) with relapsed or refractory (R/R) marginal zone lymphoma (MZL) in the phase 2 TRANSCEND FL Study. ICML 2025;Abstract 55.

Thieblemont C et al. 4-year update of phase 2 ELARA trial: Clinical outcomes of tisagenlecleucel in patients (PTS) with high-risk relapsed/refractory follicular lymphoma (R/R FL). EHA 2025;Abstract PS2150.

Trneny M et al. Tafasitamab (TAFA) plus lenalidomide (LEN) and rituximab (R) for patients with relapsed or refractory follicular lymphoma (R/R FL): Results from the phase 3 INMIND Study. EHA 2025;Abstract S230.

Vitolo U et al. Epcoritamab monotherapy demonstrates deep and durable responses at 3-year follow-up in patients with relapsed/refractory follicular lymphoma. EHA 2025;Abstract PF881.

Wang ML et al. minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Results from the phase 3 ECHO trial. EHA 2025;Abstract PF882.

 

Dr Kahl

Abramson JS et al. Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO. ASCO 2025;Abstract 7015.

Alderuccio JP et al. Initial results from LOTIS-7: A phase 1B study of loncastuximab tesirine plus glofitamab in patients with relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL). EHA 2025;Abstract PS1911.

Armand P et al. WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma. ASCO 2025;Abstract 7005.

Calabretta E et al. The benefit of POLA-R-CHP in DLBclass-defined molecular subsets of newly diagnosed DLBCL in the POLARIX trial. International Conference on Malignant Myeloma (ICML) 2025;Abstract LBA1.

Carlo-Stella C et al. Updated safety run-in results from LOTIS-5: A phase 3, randomized trial of loncastuximab tesirine with rituximab versus immunochemotherapy in patients with R/R DLBCL/HGBL. EHA 2025;Abstract PS1957.

Crombie JL et al. A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with high-risk diffuse large B-cell lymphoma. ICML 2025;Abstract 74.

Eyre TA et al. SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies. ASCO 2025;Abstract TPS7083.

Kerr D et al. Durable efficacy with fixed-duration epcoritamab + polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (POLA-R-CHP) for 1L diffuse large B-cell lymphoma (EPCORE NHL-5). EHA 2025;Abstract S247.

Kim TM et al. Safety and efficacy of AZD0486, a CD19 x CD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma. ASCO 2025;Abstract 7046.

Matasar M et al. Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (POLA-R-GEMOX) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from the randomized phase III POLARGO trial. EHA 2025;Abstract S101.

Salles G et al. Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes. ASH 2024;Abstract 469.

Shadman M et al. TITANium: An open-label, global multicenter phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r/r) B-cell malignancies. ASCO 2025;Abstract TPS7091.

Westin J et al. Mosunetuzumab plus polatuzumab vedotin is superior to R-GemOx in transplant-ineligible patients with R/R LBCL: Primary results of the phase III SUNMO trial. ICML 2025;Abstract LBA3.